HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.

Abstract
Epacadostat (EPAC) is a first-in-class, orally active inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 and has demonstrated promising clinical activity. In humans, three major plasma metabolites have been identified: M9 (a glucuronide-conjugate), M11 (a gut microbiota metabolite), and M12 (a secondary metabolite formed from M11). It is proposed, based on the human pharmacokinetics of EPAC, that the biliary excretion of M9, the most abundant metabolite, leads to the enterohepatic circulation of EPAC. Using various in vitro systems, we evaluated in the present study the vitro interactions of EPAC and its major metabolites with major drug transporters involved in drug absorption and disposition. EPAC is a substrate for efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but it is not a substrate for hepatic uptake transporters [organic anion transporting polypeptides OATP1B1 and OATP1B3]. The low permeability of M9 suggests an essential role for transporters in its disposition. M9 is likely excreted from hepatocytes into bile via multidrug resistance-associated protein 2 (MRP2) and BCRP, excreted into blood via MRP3, and transported from blood back into hepatocytes via OATP1B1 and OATP1B3. M11 and M12 are not substrates for P-gp, OATP1B1 or OATP1B3, and M11, but not M12, is a substrate for BCRP. With respect to inhibition of drug transporters, the potential of EPAC, M9, M11, and M12 to cause clinical drug-drug interactions via inhibition of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or organic cation transporter 2 was estimated to be low. The current investigation underlines the importance of metabolite-transporter interactions in the disposition of clinically relevant metabolites, which may have implications for the pharmacokinetics and drug interactions of parent drugs.
AuthorsQiang Zhang, Yan Zhang, Jason Boer, Jack G Shi, Peidi Hu, Sharon Diamond, Swamy Yeleswaram
JournalDrug metabolism and disposition: the biological fate of chemicals (Drug Metab Dispos) Vol. 45 Issue 6 Pg. 612-623 (06 2017) ISSN: 1521-009X [Electronic] United States
PMID28283500 (Publication Type: Journal Article)
CopyrightCopyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.
Chemical References
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Membrane Transport Proteins
  • Oximes
  • Sulfonamides
  • epacadostat
Topics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 (metabolism)
  • Animals
  • Biological Transport (drug effects)
  • CHO Cells
  • Caco-2 Cells
  • Cell Line
  • Cell Line, Tumor
  • Cricetulus
  • Dogs
  • Drug Interactions (physiology)
  • HEK293 Cells
  • Hepatocytes (metabolism)
  • Humans
  • Liver (metabolism)
  • Madin Darby Canine Kidney Cells
  • Membrane Transport Proteins (metabolism)
  • Oximes (metabolism, pharmacology)
  • Sulfonamides (metabolism, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: